Jiménez-Vicente, C, Arribas, I, Pomares, H, Ramil, G, Castaño-Diez, S, Pérez-Valencia, AI, Sturla, AL, López-Guerra, M, Martinez-Roca, A, Zugasti, I, Guijarro, F, Cortés-Bullich, A, Merchán, B, Triguero, A, Monge, I, Tuca, A, Oñate, G, Garrido, A, Sierra, J, Arnan, M, Esteve, J, Díaz-Beyá, M. Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia. HAEMATOLOGICA. 2025; 110(6)DOI:10.3324/haematol.2024.286589. PMID:39844754. IF:10.100(Q1/2D).

Jimenez-Vicente, C, Cardus, A, Castaño-Diez, S, Ramil, G, Garcia-Avila, S, Gomez-Perez, L, Esteban, D, Arribas, I, Sturla, AL, Lopez-Guerra, M, Martinez-Roca, A, Cortes-Bullich, A, Perez-Valencia, AI, Zugasti, I, Monge, I, Carcelero, E, Vall-Llovera, F, Vives, S, Sierra, J, Nomdedeu, J, Oñate, G, Garrido, A, Pratcorona, M, Pomares, H, Arnan, M, Guijarro, F, Diaz-Beya, M, Esteve, J. Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations. Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-025-01298-6. PMID:40368916. IF:11.600(Q1/1D).

Sobas, MA, Turki, AT, Ramiro, AV, Hernández-Sánchez, A, Elicegui, JM, González, T, Melchor, RA, Abáigar, M, Tur, L, Dall'Olio, D, Sträng, E, Tettero, JM, Castellani, G, Benner, A, Doehner, K, Thiede, C, Metzeler, KH, Haferlach, T, Damm, F, Ayala, R, Martínez-López, J, Mills, KI, Sierra, J, Lehmann, S, Della Porta, MG, Mayer, J, Reinhardt, D, Medina, RV, Schulze-Rath, R, Barbus, M, Hernández-Rivas, JM, Huntly, BJP, Ossenkoppele, G, Döhner, H, Bullinger, L. Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance. HAEMATOLOGICA. 2025; 110(5)DOI:10.3324/haematol.2024.285805. PMID:39506894. IF:10.100(Q1/2D).

Lambert, N, Forte, F, El Moussaoui, M, Monseur, J, Raus, N, Polushin, A, Michonneau, D, Shultz, C, Hogan, WJ, Balaguer-Roselló, A, Gil-Perotín, S, Brijs, J, Chauvet, P, Gavriilaki, M, Carre, M, Dulamea, AO, Chalandon, Y, Salmenniemi, U, Duminuco, A, Ram, R, García-Cadenas, I, Porto, G, Nguyen, S, Smallbone, P, González-Vicent, M, Santoro, JD, Willems, E, Baron, F, Servais, S, Beguin, Y, Maquet, P, CNS GvHD Study Grp. CNS manifestations in acute and chronic graft-versus-host disease. BRAIN. 2025; 148(4)DOI:10.1093/brain/awae340. PMID:39442000. IF:11.700(Q1/1D).

Spyridonidis, A, Labopin, M, Savani, BP, Kulagin, A, Blaise, D, Broers, AEC, Sica, S, Raiola, AM, Vydra, J, Choi, G, Rovira, M, Kwon, M, Sanz, J, Itäla-Remes, M, von dem Borne, P, Esquirol, A, Koc, Y, Brissot, E, Nagler, A, Mohty, M, Ciceri, F. The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide. BONE MARROW TRANSPLANTATION. 2025; 60(4)DOI:10.1038/s41409-025-02514-4. PMID:39910175. IF:5.200(Q1/1D).

Jiménez-Vicente, C, Esteve, J, Baile-González, M, Pérez-López, E, Calvo, CM, Aparicio, C, Ormategi, IO, Esquirol, A, Peña-Muñoz, F, Fernandez-Luis, S, Fernando, IH, González-Rodríguez, AP, López-García, A, López-Lorenzo, JL, Torrado, T, Marín, AJS, Fleytas, CA, García, L, Villar, S, Filaferro, S, Balsalobre, P, Cascón, MJP, Salas, MQ. Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC). Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-025-01223-x. PMID:40118819. IF:11.600(Q1/1D).

Navarro, S, Moukheiber, C, Sancho, SI, Guillén, MR, de Cerio, ALD, Sanges, C, Tanaka, T, Arnould, S, Briones, J, Dolstra, H, Hudecek, M, Choudhary, R, Schapitz, I, Juan, ME, Worel, N, Ammar, D, Luu, M, Mueller, M, Schroeder, B, Negre, H, Franz, P. Optimizing CAR-T treatment: A T2EVOLVE guide to raw and starting material selection. MOLECULAR THERAPY. 2025; 33(3)DOI:10.1016/j.ymthe.2024.11.017. PMID:39533710. IF:12.000(Q1/1D).

Escamilla-Gómez, V, Gutiérrez, VG, Alcalde-Mellado, P, Astibia-Mahillo, B, Chinea-Rodriguez, A, López-Corral, L, Acera-Gómez, M, Ochando, MKT, Borrego, AB, Pinedo, LG, Ripa, TZ, Vicent, MG, Benzaquén, A, García, II, Cantó, PA, Montoro, J, Martín-Domínguez, FM, Orti, G, Valcárcel, D, Benitez-Carabante, MI, Diaz-de-Heredia, C, Cañamero, E, Ferrá, C, García-Cadenas, I, Redondo, S, Sisinni, L, Perez-Martínez, A, Mussetti, A, Garcia-Mañó, L, Palomo-Moraleda, MD, González-Sierra, PA, Jurado, M, Perez-Simon, JA. Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC. BONE MARROW TRANSPLANTATION. 2025; 60(3)DOI:10.1038/s41409-024-02483-0. PMID:39663471. IF:5.200(Q1/1D).